相关实验视频

Updated: May 10, 2025

Gastric Mucosa Quantitative Polymerase Chain Reaction Analysis for Detecting Helicobacter pylori and Antibiotic Resistance

Gastric Mucosa Quantitative Polymerase Chain Reaction Analysis for Detecting Helicobacter pylori and Antibiotic Resistance

Published on: March 7, 2025

穿透和响应胃粘液的微凝用于缓解Helicobacter pylori诱导的胃炎

Xing Li¹, Jipeng Zhang², Xiangyu Liu¹

¹Research Center of Food Colloids and Delivery of Functionality, College of Food Science and Nutritional Engineering, China Agricultural University, Beijing 100083, China.

Journal of controlled release : official journal of the Controlled Release Society

|April 27, 2025

概括

一种新型的微凝系统有效地提供硫 (SFN) 来对抗Helicobacter pylori (H. pylori) 感染. 这种胃反应性输送增强了SFN.

科学领域:

胃肠病学胃肠病学
药物输送系统药物输送系统
微生物学微生物学

背景情况:

杆菌 (H. pylori) 感染是全球胃炎和胃癌的主要原因之一.
硫 (SFN) 是一种天然化合物,对抗H. pylori有希望,但稳定性不佳.
需要有效的传递系统来克服SFN对H. pylori治疗的限制.

研究的目的:

开发一种胃敏感的微凝,用于针对H.pylori的SFN的向输送.
为了评估SFN装载微凝的稳定性,释放动力学和有效性.
在H. pylori感染的小鼠模型中评估微凝系统的治疗潜力.

主要方法:

酸盐涂层微凝 (CTS-MGs) 是使用装载着SFN的α-乳蛋白纳米管制造的.
在体外研究中评估了SFN负载,胃粘附和响应释放.
活体疗效在感染H. pylori的小鼠中进行了评估,评估了胃炎和胃微生物群.

主要成果:

装有SFN的CTS-MG显示了高负载效率 (10.73%) 和强大的胃粘膜粘附.
微凝在胃中持续释放SFN,并穿透粘液层.
在小鼠中,口服CTS-MG/SFN显著降低了H. pylori负载,缓解了胃炎,并恢复了胃微生物群平衡.

结论:

胃敏感的酸盐涂层微凝提供了一个有前途的策略,用于口服输送SFN对抗H. pylori.
这种输送系统通过改善胃保留和向释放来提高SFN的有效性.
开发的微凝具有治疗H. pylori感染和相关胃病的潜力.

关键词:

抗Helicobacter pylori病毒感染的感染.对胃有针对性的分娩微凝是一种微凝.硫甲是一种硫甲.一个α-乳蛋白纳米管.

更多相关视频

One-step Negative Chromatographic Purification of Helicobacter pylori Neutrophil-activating Protein Overexpressed in Escherichia coli in Batch Mode

One-step Negative Chromatographic Purification of Helicobacter pylori Neutrophil-activating Protein Overexpressed in Escherichia coli in Batch Mode

Published on: June 18, 2016

Mouse Models Of Helicobacter Infection And Gastric Pathologies

Mouse Models Of Helicobacter Infection And Gastric Pathologies

Published on: October 18, 2018

相关概念视频

Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy

Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy

Helicobacter pylori, a resilient gram-negative bacterium, can thrive in the stomach's harsh, acidic environment. Infection with H. pylori leads to a cascade of events within the stomach lining. One of the critical disruptions caused by this bacterium is the interference with somatostatin production, a hormone responsible for regulating acid secretion. This interference tips the balance, escalating acid secretion and diminishing bicarbonate levels. This imbalance compromises the defensive...

Mucosal Barrier of the Stomach

Mucosal Barrier of the Stomach

The gastric glands contain parietal cells that secrete hydrochloric acid (HCl) for digestion. The cells secrete HCl because it is highly corrosive and essential for breaking down food. To achieve this, they secrete hydrogen and chloride ions into the lumen of the gastric glands, which combine to form HCl.
Within parietal cells, carbonic acid is first formed through the reaction of water and carbon dioxide. The dissociation of carbonic acid releases bicarbonate and hydrogen ions. The bicarbonate...

Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents

Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents

The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...

Peptic Ulcer Disease IV: Management

Peptic Ulcer Disease IV: Management

Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...

Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors

Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors

Peptic ulcers, often induced by H. pylori infections or NSAID usage, arise from disruptions in the delicate balance of gastric acid production. Peptic ulcers stem from heightened gastric acid levels due to H. pylori infections or NSAID use. The protective mucus layer diminishes in the presence of these factors, allowing gastric acid to erode the stomach lining and form ulcers.
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...

Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors

Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors

Peptic ulcer disease, commonly called PUD, represents a multifaceted condition characterized by disruptions in the lining of the gastrointestinal (GI) tract. Central to the protection of the gastrointestinal lining is the mucosal-bicarbonate barrier. This physiological defense mechanism is a formidable shield against the corrosive effects of gastric acid and pepsin secretion in the stomach. Its role is pivotal in maintaining the structural integrity of the stomach's inner lining.